The role of interleukin-17 in spondyloarthropathies and systemic lupus erythematosus: Two clinical cases in real
Authors:
Open Access
- 19 January 2022
- journal article
- research article
- Published by Peertechz Publications Private Limited in Global Journal of Medical and Clinical Case Reports
- Vol. 9 (1) , 004-007
Abstract
Spondyloarthropathies are known to affect the interleukin (IL)-17 activation pathway as a basis of their pathology, as is apparent from the literature. Recent studies established the vital role of IL-17 in the treatment of Systemic Lupus Erythematosus (SLE). This article aims to demonstrate the efficacy and safety of IL-17 in the treatment of both spondyloarthropathies and SLE by presenting two cases. The first case concerns a 30-year-old woman who was initially diagnosed with SLE. In the course of the disease, she developed spondyloarthritis and genital psoriasis. She was initially medicated with secukinumab but maintained severe genital psoriasis, the reason it was changed to ixekizumab with great improvement. The second case refers to a 40-year-old woman who previously had spondyloarthropathy with D12 enthesitis and sacroiliitis. Initial treatment with adalimumab led to a lupus-like syndrome, with persistent high systemic inflammatory response syndrome and extreme fatigue. Because of the recrudescence of axial complaints, secukinumab was started and the patient evolved with a global clinical response. Thus, the authors present two cases of spondyloarthropathy and SLE that document the efficacy and safety of IL- 17 blockers, which can lead to the incorporation of these agents in the treatment of SLE.Keywords
This publication has 18 references indexed in Scilit:
- Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasisBritish Journal of Dermatology, 2018
- Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2RMD Open, 2017
- Inhibition of IL‐17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infectionsClinical & Translational Immunology, 2017
- Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 studyAnnals of the Rheumatic Diseases, 2017
- Plasma IL-17A Is Increased in New-Onset SLE Patients and Associated with Disease ActivityJournal of Clinical Immunology, 2010
- Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: Implications for Th17-mediated inflammation in auto-immunityClinical Immunology, 2008
- Interleukin 17–producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 miceNature Immunology, 2007
- Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destructionJournal of Experimental Medicine, 2006
- Production of a novel class of polyreactive pathogenic autoantibodies in BXD2 mice causes glomerulonephritis and arthritisArthritis & Rheumatism, 2005
- Suppression of Immune Induction of Collagen-Induced Arthritis in IL-17-Deficient MiceThe Journal of Immunology, 2003